Abstract
Objectives: Invasive fungal infections (IFI) remain a main cause of death after heart surgery, in spite of the advances in pharmacological therapy. Anidulafungin is a new echinocandin with high efficacy against IFI in haematological patients and a reported low renal toxicity. Our aim was to assess the empirical use of Anidulafungin in high-risk patients with suspected IFI at the ICU after heart surgery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
